On-Demand Webinar: Characterizing Anti-HER2 Antibodies with Advanced Flow Cytometry & BLI Label-Free Detection
Overview
Antibody-based therapeutics are helping patients across a wide range of disease areas, from cancer, such as Rituximab treatment of CD20-positive non-Hodgkin's lymphomas, to infectious diseases like SARS-CoV-2 and HIV. Conventional techniques used in antibody discovery workflows are often limited due to low-throughput sample acquisition, large sample volume requirements, and challenges around analyzing complex datasets. The development of novel antibody therapeutics relies on high-throughput technologies with powerful analysis capabilities that can reliably screen and profile drug candidates.
- Document type: Webinar
- Watch time: 41 minutes
View This Webinar to Learn About:
- Combining the iQue® Advanced Flow Cytometry and Octet® BLI Label-Free Detection platforms to characterize antibodies during drug discovery
- Using the iQue® and associated reagent kits for high-throughput analysis of live-cell antibody binding, competitive binding, and Fc function
- Determination of ligand and Fc-gamma receptor binding kinetics through robust measurements with the Octet® system
Webinar Speaker
Kirsty McBain
Scientist, BioAnalytics
Sartorius
Kirsty McBain is a Scientist in the BioAnalytics applications group at Sartorius where she is involved in research and development of novel applications for the iQue® advanced flow cytometry platform.
She has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.
David Apiyo, Ph.D.
Senior Manager, Applications
Sartorius
David is a Senior Manager of Applications at Sartorius, focused on Octet label-free detection platforms and applications. In this role, he leads a team of Applications Managers and is responsible for the strategic direction of the GMP/GxP and bioprocessing vertical markets.
David started out as a Field Applications Scientist in 2011 and transitioned to the marketing applications team in 2015. Prior to this, David worked as a Senior Development Scientist, R&D department, at Beckman Coulter where he was involved in the development and validation of protein and antibody conjugate chemistries.
David obtained his Ph.D. in Protein Chemistry from Tulane University, New Orleans.